Therapeutic Strategy Details
| Strategy ID: | S16 |
| Strategy: | Immunotherapy |
| Other Terms: | None |
| Related Targets: | None |
| Related Drugs: | None |
| Mechanism: | NASH is one of important drivers of hepatocellular carcinoma (HCC), and immunotherapy is considered to activate T cells or reinvigorate immune surveillance against cancer, with a response rate of 15-30% in patients with HCC. |
| Reference (PMIDs): | 20557969; 33762733 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0233 | DB00668 | approved; vet_approved | small molecule | Epinephrine | Target associated | Details |
| R0309 | DB00853 | approved; investigational | small molecule | Temozolomide | Therapeutic strategy associated | Details |
| R1213 | DB09077 | approved; investigational | biotech | Dinutuximab | Therapeutic strategy associated | Details |
| R1501 | DB13915 | approved | biotech | Axicabtagene ciloleucel | Therapeutic strategy associated | Details |
| R1569 | DB15699 | approved | biotech | Brexucabtagene autoleucel | Therapeutic strategy associated | Details |
| R1571 | DB15721 | investigational | biotech | Natural Killer Cell | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00062 | 35235789 | Cell Rep | Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma. | Details |
| A00765 | 34975333 | Int J Biol Sci | Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential. | Details |
| A00941 | 34923459 | Wiad Lek | THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | Details |
| A01058 | 34884762 | Int J Mol Sci | Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. | Details |
| A01952 | 34555422 | J Hepatol | NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. | Details |
| A02478 | 34359642 | Cancers (Basel) | The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. | Details |
| A02834 | 34225438 | Zhonghua Gan Zang Bing Za Zhi | [Mechanism of T lymphocyte subsets in the malignant transformation of non-alcoholic fatty liver disease]. | Details |
| A03078 | 34139486 | ESMO Open | Cancer and hepatic steatosis. | Details |
| A03831 | 33854987 | J Hepatocell Carcinoma | NAFLD-Associated HCC: Progress and Opportunities. | Details |
| A04094 | 33762733 | Nature | NASH limits anti-tumour surveillance in immunotherapy-treated HCC. | Details |
| A04176 | 33727658 | Commun Biol | Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes. | Details |
| A04564 | 33578800 | Cancers (Basel) | Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. | Details |
| A04691 | 33541087 | Chin Clin Oncol | Epidemiology, mutational landscape and staging of hepatocellular carcinoma. | Details |
| A04770 | 33511275 | Clin Exp Hepatol | Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. | Details |
| A06092 | 33010248 | Gastroenterology | Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. | Details |
| A07008 | 32660172 | Zhonghua Gan Zang Bing Za Zhi | [Carcinoembryonic type specific markers and liver cancer immunotherapy]. | Details |
| A07009 | 32660170 | Zhonghua Gan Zang Bing Za Zhi | [Strategies and challenges of immunotherapy for hepatocellular carcinoma]. | Details |
| A07354 | 32527116 | Chin Clin Oncol | Hepatocellular carcinoma, novel therapies on the horizon. | Details |
| A07372 | 32523311 | World J Gastroenterol | Role of γδT cells in liver diseases and its relationship with intestinal microbiota. | Details |
| A08875 | 31954491 | J Hepatol | Advances in resection and transplantation for hepatocellular carcinoma. | Details |